Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 31 of 95, showing 5 Applications out of 474 total, starting on record 151, ending on 155

# Protocol No Study Title Investigator(s) & Site(s)

151.

ECCT/17/05/02   The Anza Mapema Study
    Expanding test and treat for HIV prevention in MSM in Kisumu, Kenya: The Anza Mapema Study   
Principal Investigator(s)
1. Fredrick Odhiambo Otieno
Site(s) in Kenya
Anza Mapema Study Clinic
 
View

152.

ECCT/17/05/03   TDF IVR-002 Study
    Phase 1 Safety and Pharmacokinetic Study of a Polyurethane Tenofovir Disoproxil Fumarate Vaginal Ring in Sexually Active Women (TDF IVR-002)   
Principal Investigator(s)
1. Nelly Rwamba Mugo
Site(s) in Kenya
Partners in Health Research & Development (Thika Partners Clinical Trial Site)
 
View

153.

ECCT/17/05/04   Ad26.Mos4.HIV Prime/Ad26.Mos4.HIV with Clade C gp140 plus adjuvant +/- Mosaic boost
    A randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in healthy HIV-uninfected adults to assess safety/tolerability and immunogenicity of 2 different prime/boost regimens: priming with tetravalent Ad26.Mos4.HIV and boosting with tetravalent Ad26.Mos4.HIV and either Clade C gp140 plus adjuvant OR a combination of Mosaic and Clade C gp140 plus adjuvant   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
KEMRI WALTER REED KERICHO
 
View

154.

ECCT/17/06/01   MF/PM Phase III
    An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin with Sodium Stibogluconate and Paromomycin Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa       
Principal Investigator(s)
1. Jane Mbui
Site(s) in Kenya
1. Kimalel Health Centre (Baringo county)
2. Kacheliba sub-county hospital (West Pokot county)
 
View

155.

ECCT/17/06/02   PAINT Study
    A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years   
Principal Investigator(s)
1. Isaac Tsikhutsu
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county)
2. KAVI Institute of Clinical Research (Nairobi City county)
 
View